State-of-the-Art in Combination Immuno/Radiotherapy for Non-Small Cell Lung Cancer

meeting/webinar banner
Overview

This webinar will explore the expected benefits, toxicities and potential indications for the combination of immunotherapy and radiotherapy. Both are often used in the care of patients with non-small cell lung cancer, typically with non-overlapping indications for use. Topics will include the preclinical and clinical evidence and rationale for combining radiotherapy and immunotherapy.

Wednesday, January 20
1pm MST
3pm EST
8pm GMT (UK)

Thursday, January 21 
7am AEDT (AU)

Format: 1 hour webinar. Two 20-minute presentations followed by a 20-minute Q and A.

Date
Jan 20, 2021 -
Jan 20, 2021
Location

Online

CME Accredited
Presenters
Shankar Siva, MBBS, FRANZCR, PhD
Shankar Siva, MBBS, FRANZCR, PhD

Shankar Siva, MBBS, FRANZCR, PhD
Associate Professor, Radiation Oncology
University of Melbourne, Peter MaCallum Cancer Centre
Melbourne, Australia  

 

 

 

 

 

 

 

 

Willemijn S.M.E. Theelen, MD, PhD
Willemijn S.M.E. Theelen, MD, PhD

Willemijn S.M.E. Theelen, MD, PhD
Pulmonologist at the Netherlands Cancer Institute
Amsterdam, Netherlands

 
 
 
 
 
 
 
 
 
 
 
Moderator
Corinne Faivre-Finn, FRCR, MD, PhD
Corinne Faivre-Finn, FRCR, MD, PhD

Corinne Faivre-Finn, FRCR, MD, PhD
Professor of Thoracic Radiation Oncology, Consultant Clinical Oncologist,
University of Manchester & The Christie NHS Foundation Trust

At the end of the webinar, learners will be able to:  

  1. Understand the preclinical rationale for synergy in combining radiotherapy and immunotherapy.
  2. Understand the unresolved questions around sequencing, dose/fractionation, abscopal effects, and sites of irradiation in combination therapy.
  3. Understand pertinent clinical trial evidence for the safety and efficacy of radiotherapy and immunotherapy combinations.
  4. Update key ongoing trials of RT-IO combo in the curative, oligometastatic and metastatic setting.

Physicians and researchers specializing in medical oncology, radiation oncology, pathology, pulmonary medicine and cancer research.

Accreditation Statement

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Disclosures

Faculty and Planners

Corinne Faivre-Finn, FRCR MD PhD discloses she receives research funding from Astra Zeneca, MSD Pharmaceuticals and Elekta and is on an advisory board and scientific committees for Astra Zeneca.

Shankar Siva, MBBS, FRANZCR, PhD discloses he is on an advisory board and is a consultant for Astra Zeneca and has a research grant from Varian Medical Systems.

Willemijn S.M.E. Theelen, MD PhD discloses she is an investigator for Astra Zeneca.

Kirsten Black, PhD, MPH has no financial relationships to disclose.

Aubrey Shoe, MA has no financial relationships to disclose.

All other planners, reviewers and staff reported no relevant financial relationships. All relevant financial relationships have been mitigated.

Presenters
Shankar Siva, MBBS, FRANZCR, PhD
Shankar Siva, MBBS, FRANZCR, PhD

Shankar Siva, MBBS, FRANZCR, PhD
Associate Professor, Radiation Oncology
University of Melbourne, Peter MaCallum Cancer Centre
Melbourne, Australia  

 

 

 

 

 

 

 

 

Willemijn S.M.E. Theelen, MD, PhD
Willemijn S.M.E. Theelen, MD, PhD

Willemijn S.M.E. Theelen, MD, PhD
Pulmonologist at the Netherlands Cancer Institute
Amsterdam, Netherlands

 
 
 
 
 
 
 
 
 
 
 
Moderator
Corinne Faivre-Finn, FRCR, MD, PhD
Corinne Faivre-Finn, FRCR, MD, PhD

Corinne Faivre-Finn, FRCR, MD, PhD
Professor of Thoracic Radiation Oncology, Consultant Clinical Oncologist,
University of Manchester & The Christie NHS Foundation Trust

At the end of the webinar, learners will be able to:  

  1. Understand the preclinical rationale for synergy in combining radiotherapy and immunotherapy.
  2. Understand the unresolved questions around sequencing, dose/fractionation, abscopal effects, and sites of irradiation in combination therapy.
  3. Understand pertinent clinical trial evidence for the safety and efficacy of radiotherapy and immunotherapy combinations.
  4. Update key ongoing trials of RT-IO combo in the curative, oligometastatic and metastatic setting.

Physicians and researchers specializing in medical oncology, radiation oncology, pathology, pulmonary medicine and cancer research.

Accreditation Statement

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Disclosures

Faculty and Planners

Corinne Faivre-Finn, FRCR MD PhD discloses she receives research funding from Astra Zeneca, MSD Pharmaceuticals and Elekta and is on an advisory board and scientific committees for Astra Zeneca.

Shankar Siva, MBBS, FRANZCR, PhD discloses he is on an advisory board and is a consultant for Astra Zeneca and has a research grant from Varian Medical Systems.

Willemijn S.M.E. Theelen, MD PhD discloses she is an investigator for Astra Zeneca.

Kirsten Black, PhD, MPH has no financial relationships to disclose.

Aubrey Shoe, MA has no financial relationships to disclose.

All other planners, reviewers and staff reported no relevant financial relationships. All relevant financial relationships have been mitigated.

Share

Interested in advertising and exhibit opportunities?